Article Text

Download PDFPDF

Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

Statistics from Altmetric.com

Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Science, Medicine 2018;5:e000286. doi: 10.1136/lupus-2018-000286

This article has been corrected since it first published. This is to inform that co-author Wendy I White’s affiliation was addressed incorrectly. Her correct affiliation is: Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA.

Below is the updated information on the authors’ affiliation.

Kerry A Casey,1 Xiang Guo,2 Michael A Smith,1 Shiliang Wang,2 Dominic Sinibaldi,3 Miguel A Sanjuan,1 Liangwei Wang,4 Gabor G Illei,5 Wendy I White2

1Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, Maryland, USA

2Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA

3Research Bioinformatics, MedImmune LLC, Gaithersburg, Maryland, USA

4Biostatistics, MedImmune LLC, Gaithersburg, Maryland, USA

5Clinical Development, MedImmune LLC, Gaithersburg, Maryland, USA

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.